<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022239</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0972</org_study_id>
    <secondary_id>NCI-2019-03900</secondary_id>
    <secondary_id>2018-0972</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04022239</nct_id>
  </id_info>
  <brief_title>Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant</brief_title>
  <official_title>Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of bendamustine when given with
      or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients
      undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and
      cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
      killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
      chemotherapy and total body irradiation before or after a stem cell transplant helps kills
      cancer cells that are in the body and helps make room in the patient's bone marrow for new
      blood-forming cells (stem cells) to grow. Sometimes, the transplanted cells from a donor can
      attack the body's normal cells called GVHD. Giving tacrolimus, mycophenolate mofetil, and
      filgrastim after the transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety of substituting the standard post-transplant cyclophosphamide (PT-CY)
      given on day +3 and +4 with post-transplant bendamustine (PT-BEN) in patients undergoing
      HLA-mismatched hematopoietic cell transplantation.

      SECONDARY OBJECTIVES:

      I. To evaluate treatment-related mortality. II. To assess acute and chronic graft-versus-host
      disease (GVHD). III. To assess overall survival, progression-free survival and relapse rates.
      IV. To evaluate the risk of acute cystitis. V. To evaluate immune reconstitution after
      transplantation.

      OUTLINE: This is a dose-escalation study of bendamustine. Patients are assigned to 1 of 2
      treatment schedules.

      SCHEDULE I (NON-LYMPHOMA): Patients receive fludarabine intravenously (IV) over 1 hour on
      days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo total body
      irradiation (TBI) on day -1 and stem cell transplantation IV over 2-6 hours on day 0.
      Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or
      bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV
      over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day
      4. Beginning day 5, patients receive tacrolimus IV followed by orally (PO) once daily (QD) or
      twice daily (BID) for 6 months and mycophenolate mofetil PO thrice daily (TID) until day 100.
      Beginning day 7, patients receive filgrastim-sndz subcutaneously (SC) QD until blood cell
      levels return to normal.

      SCHEDULE II (LYMPHOID MALIGNANCIES): Patients receive fludarabine IV over 1 hour,
      bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell
      transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients
      receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or
      cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients
      also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive
      tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until
      day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels
      return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and
      8.

      After completion of study treatment, patients are followed weekly for 3 months, every 3
      months in year 1, and every 6 months in year 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose level (MTDL) (Phase I)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will employ the time-to-event Bayesian optimal interval design to find the MTDL. After the trial is completed, the MTDL will be selected based on isotonic regression as specified in Yuan et al. Specifically, MTDL will be selected as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate. If there are ties, the higher dose level when the isotonic estimate is lower than the target toxicity rate will be selected and the lower dose level when the isotonic estimate is greater than or equal to the target toxicity rate will be selected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (Phase I)</measure>
    <time_frame>Up to 100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The trial is continuously monitored for toxicity per the statistical design.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplant Recipient</condition>
  <condition>Donor</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo stem cell transplantation</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>SDX-105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>Bendamustin Hydrochloride</other_name>
    <other_name>Bendeka</other_name>
    <other_name>Cytostasan Hydrochloride</other_name>
    <other_name>Levact</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>SyB L-0501</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Schedule I (non-lymphoma)</arm_group_label>
    <arm_group_label>Schedule II (lymphoid malignancies)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age 18 to 65 with hematologic malignancies

          2. Eligible to receive an reduced-intensity allogeneic HCT

          3. Donor: Mismatched or haplo-identical

          4. Zubrod performance 0 to 2 or Karnofsky of at least 60.

          5. Adequate organ function at time of study entry: a. Creatinine less than or equal to
             1.6 mg/dL. b. Total bilirubin less than &lt; 1.5 x UNL. c. SGPT &lt; 2.5 x ULN. d. Ejection
             fraction &gt;/= 40%. e. FEV1, FVC and DLCO &gt;/= 40%.

        Exclusion Criteria:

          1. Pregnant or nursing women

          2. Known to be HIV positive

          3. Active and uncontrolled disease/infection

          4. Unable or unwilling to sign consent

          5. Current active hepatic or biliary disease (with exception of Gilbert's syndrome)

          6. Active hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F Khouri</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Issa F Khouri</last_name>
    <phone>713-792-8750</phone>
    <email>ikhouri@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Issa F. Khouri</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Issa F. Khouri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

